It is a recombinant DNA-produced analogue of the human enzyme \u03b2-glucocerebrosidase. Cerezyme is a freeze-dried medicine containing imiglucerase, manufactured by Genzyme Corporation. It is given intravenously after reconstitution as a treatment for Type 1 and Type 3 Gaucher’s disease. Cerezyme was one of the drugs manufactured at Genzyme’s Allston, Massachusetts plant, for which production was disrupted in 2009 after contamination with Vesivirus 2017.<\/p>\n
Cerezyme (imiglucerase) is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant non-neurological manifestations of the disease.
\nThe non-neurological manifestations of Gaucher disease include one or more of the following conditions:
\n\u2022 anaemia after exclusion of other causes, such as iron deficiency
\n\u2022 thrombocytopenia
\n\u2022 bone disease after exclusion of other causes such as Vitamin D deficiency
\n\u2022 hepatomegaly or splenomegaly<\/p>\n
If imiglucerase for infusion are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n
Note:<\/strong> Cerezyme is used for the long-term treatment of patients with Gaucher disease. Gaucher disease is a rare inherited disorder, in which people do not have enough of an enzyme called acid beta-glucosidase, which normally breaks down a fatty waste product called glucosylceramide. Without the enzyme, glucosylceramide builds up in the body, typically in the liver, spleen and bone marrow, which produces the symptoms of the disease: anaemia (low red blood cell counts), tiredness, easy bruising and a tendency to bleed, an enlarged spleen and liver, and bone pain and breaks.<\/p>\n Approval Date: 1998 If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import Cerezyme for infusion\u201d based on the information you provide.<\/p>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.<\/p>\nReferences<\/h3>\n
\n
\nSee Drugs@FDA for information about all of CDER\u2019s approved drugs and biological products.<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"Cerezyme 400 Units
\nPowder for concentrate for solution for infusion<\/h2>\nFacts about Cerezyme for infusion<\/h4>\n
\nProprietary Name: On Request
\nActive Ingredient(s): imiglucerase for infusion
\nDosage Forms And Strengths: Cerezyme is supplied in type I borosilicate (clear) glass 20 ml vials. The closure consists of a
\nsiliconised butyl stopper with a tamper proof flip-off cap. Pack sizes: 1, 5 or 25 vials per carton
\n<\/strong>International non-proprietary name (INN) or common name: imiglucerase
\nTherapeutic area (MeSH): Gaucher Disease
\nAnatomical therapeutic chemical (ATC) code: A16AB02
\nMarketing: Sanofi B.V.
\nEMA Approved: 17\/11\/1997
\nSummary of FDA approved use on approval date:<\/strong>\u00a0Click Here<\/a><\/p>\nAccess the best support services globally<\/h4>\n